UA79463C2 - Perindopril salt and pharmaceutical composition containing thereof - Google Patents
Perindopril salt and pharmaceutical composition containing thereof Download PDFInfo
- Publication number
- UA79463C2 UA79463C2 UA20041109440A UA20041109440A UA79463C2 UA 79463 C2 UA79463 C2 UA 79463C2 UA 20041109440 A UA20041109440 A UA 20041109440A UA 20041109440 A UA20041109440 A UA 20041109440A UA 79463 C2 UA79463 C2 UA 79463C2
- Authority
- UA
- Ukraine
- Prior art keywords
- perindopril
- salt
- pharmaceutical composition
- arginine salt
- composition according
- Prior art date
Links
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical class C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract 2
- 229960002582 perindopril Drugs 0.000 claims description 20
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 15
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 11
- 150000001483 arginine derivatives Chemical class 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- RYCSJJXKEWBUTI-YDYAIEMNSA-N perindopril arginine Chemical class OC(=O)[C@@H](N)CCCNC(N)=N.C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 RYCSJJXKEWBUTI-YDYAIEMNSA-N 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical class CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204847A FR2838648B1 (fr) | 2002-04-18 | 2002-04-18 | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
PCT/FR2003/000507 WO2003087050A2 (fr) | 2002-04-18 | 2003-02-17 | Sel de perindopril et les compositions pharmaceutiques qui le contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
UA79463C2 true UA79463C2 (en) | 2007-06-25 |
Family
ID=8871521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA20041109440A UA79463C2 (en) | 2002-04-18 | 2003-02-17 | Perindopril salt and pharmaceutical composition containing thereof |
Country Status (38)
Country | Link |
---|---|
US (1) | US6696481B2 (pl) |
EP (1) | EP1354873B1 (pl) |
JP (1) | JP3737488B2 (pl) |
KR (1) | KR100542468B1 (pl) |
CN (1) | CN1211365C (pl) |
AP (1) | AP1787A (pl) |
AR (1) | AR039428A1 (pl) |
AT (1) | ATE271036T1 (pl) |
AU (2) | AU2003222921A1 (pl) |
BR (1) | BR0300709A (pl) |
CA (1) | CA2423825C (pl) |
CR (1) | CR7576A (pl) |
DE (1) | DE60300011T2 (pl) |
DK (1) | DK1354873T3 (pl) |
EA (1) | EA005676B1 (pl) |
EC (1) | ECSP045441A (pl) |
ES (1) | ES2224092T3 (pl) |
FR (1) | FR2838648B1 (pl) |
GE (1) | GEP20074211B (pl) |
HK (1) | HK1057367A1 (pl) |
HR (1) | HRP20041079B1 (pl) |
IL (1) | IL164424A (pl) |
IS (1) | IS2842B (pl) |
MA (1) | MA27115A1 (pl) |
ME (1) | ME00454B (pl) |
MX (1) | MXPA03002346A (pl) |
NO (1) | NO324323B1 (pl) |
NZ (1) | NZ524478A (pl) |
OA (1) | OA12806A (pl) |
PL (1) | PL359321A1 (pl) |
PT (1) | PT1354873E (pl) |
RS (1) | RS51694B (pl) |
SI (1) | SI1354873T1 (pl) |
TN (1) | TNSN04206A1 (pl) |
TR (1) | TR200401793T4 (pl) |
UA (1) | UA79463C2 (pl) |
WO (1) | WO2003087050A2 (pl) |
ZA (1) | ZA200301395B (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2395195A (en) * | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
WO2005094793A1 (en) | 2004-03-29 | 2005-10-13 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for preparing a solid pharmaceutical composition |
SI21800A (sl) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
ATE409036T1 (de) * | 2005-01-06 | 2008-10-15 | Ipca Lab Ltd | Verfahren zur synthese von (2s,3as,7as)-1-(s)- alanyl-octahydro-1h-2-carbonsäurederivaten und verwendung in der synthese von perindopril |
RS51147B (sr) * | 2005-03-14 | 2010-10-31 | Les Laboratoires Servier | Poboljšani postupak za prečišćavanje perindoprila |
FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
FR2897866B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2897865B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
SI22542A (sl) * | 2007-06-04 | 2008-12-31 | Diagen D.O.O. | Stabilna formulacija amorfnih soli perindoprila, postopek za njeno pripravo v industrijskem merilu in njena uporaba za zdravljenje hipertenzije |
CA2729604C (en) | 2008-06-24 | 2017-12-05 | Matrix Laboratories Ltd. | Polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
AU2009212902A1 (en) * | 2008-09-03 | 2010-03-18 | Apotex Pharmachem Inc. | Amorphous form of an L-arginine salt of perindopril and processes of preparation thereof |
CN101766598A (zh) * | 2008-12-31 | 2010-07-07 | 东英(江苏)药业有限公司 | 含有培哚普利的药物组合物 |
GB0910692D0 (en) * | 2009-06-20 | 2009-08-05 | Teva Pharma | Compound |
SI23149A (sl) | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
FR2985512B1 (fr) | 2012-01-05 | 2014-06-20 | Servier Lab | Procede de preparation du sel de l-arginine du perindopril |
FR2985511B1 (fr) | 2012-01-05 | 2014-01-03 | Servier Lab | Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
CN103172696B (zh) * | 2012-12-19 | 2014-12-17 | 宁波美诺华药业股份有限公司 | 一种γ晶型的培哚普利精氨酸盐的制备方法 |
FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
FR2811320B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2002
- 2002-04-18 FR FR0204847A patent/FR2838648B1/fr not_active Expired - Lifetime
-
2003
- 2003-02-17 EP EP03290383A patent/EP1354873B1/fr not_active Expired - Lifetime
- 2003-02-17 GE GEAP8501A patent/GEP20074211B/en unknown
- 2003-02-17 SI SI200330002T patent/SI1354873T1/xx unknown
- 2003-02-17 PT PT03290383T patent/PT1354873E/pt unknown
- 2003-02-17 AU AU2003222921A patent/AU2003222921A1/en not_active Abandoned
- 2003-02-17 DK DK03290383T patent/DK1354873T3/da active
- 2003-02-17 AT AT03290383T patent/ATE271036T1/de active
- 2003-02-17 TR TR2004/01793T patent/TR200401793T4/xx unknown
- 2003-02-17 DE DE60300011T patent/DE60300011T2/de not_active Expired - Lifetime
- 2003-02-17 RS YU90904A patent/RS51694B/en unknown
- 2003-02-17 OA OA1200400279A patent/OA12806A/en unknown
- 2003-02-17 ME MEP-2008-688A patent/ME00454B/me unknown
- 2003-02-17 UA UA20041109440A patent/UA79463C2/uk unknown
- 2003-02-17 WO PCT/FR2003/000507 patent/WO2003087050A2/fr active Application Filing
- 2003-02-17 AP APAP/P/2004/003154A patent/AP1787A/en active
- 2003-02-17 ES ES03290383T patent/ES2224092T3/es not_active Expired - Lifetime
- 2003-02-20 ZA ZA200301395A patent/ZA200301395B/xx unknown
- 2003-02-21 US US10/371,865 patent/US6696481B2/en not_active Expired - Lifetime
- 2003-02-24 NO NO20030849A patent/NO324323B1/no not_active IP Right Cessation
- 2003-02-27 AU AU2003200700A patent/AU2003200700C1/en not_active Revoked
- 2003-02-28 NZ NZ524478A patent/NZ524478A/en not_active IP Right Cessation
- 2003-03-07 CN CNB031071481A patent/CN1211365C/zh not_active Expired - Lifetime
- 2003-03-18 MX MXPA03002346A patent/MXPA03002346A/es active IP Right Grant
- 2003-03-20 KR KR1020030017434A patent/KR100542468B1/ko active IP Right Grant
- 2003-03-21 BR BR0300709-0A patent/BR0300709A/pt not_active Application Discontinuation
- 2003-03-24 PL PL03359321A patent/PL359321A1/pl not_active Application Discontinuation
- 2003-03-25 JP JP2003083250A patent/JP3737488B2/ja not_active Expired - Lifetime
- 2003-04-03 CA CA002423825A patent/CA2423825C/fr not_active Expired - Fee Related
- 2003-04-03 EA EA200300334A patent/EA005676B1/ru unknown
- 2003-04-16 AR ARP030101332A patent/AR039428A1/es not_active Application Discontinuation
-
2004
- 2004-01-10 HK HK04100189A patent/HK1057367A1/xx not_active IP Right Cessation
- 2004-10-05 IL IL164424A patent/IL164424A/en active IP Right Grant
- 2004-10-15 TN TNP2004000206A patent/TNSN04206A1/en unknown
- 2004-10-27 IS IS7516A patent/IS2842B/is unknown
- 2004-11-03 MA MA27926A patent/MA27115A1/fr unknown
- 2004-11-17 HR HRP20041079AA patent/HRP20041079B1/hr not_active IP Right Cessation
- 2004-11-18 EC EC2004005441A patent/ECSP045441A/es unknown
- 2004-11-18 CR CR7576A patent/CR7576A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA79463C2 (en) | Perindopril salt and pharmaceutical composition containing thereof | |
CA2400155C (en) | A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | |
ES2212547T3 (es) | Nuevas formas de preparados galenicas del principio activo meloxicam. | |
US4748174A (en) | Water soluble salts of an NSAID with meglumine/glucamine | |
GT200000171A (es) | Compuestos farmaceuticamente activos. | |
SK3612000A3 (en) | Sustained release tablet formulation to treat parkinson disease | |
WO1999052525A1 (es) | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos | |
ES2348942T3 (es) | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato. | |
ES2282469T3 (es) | Combinacion de un nsaid y un inhibidor de pde-4. | |
JP2001506600A (ja) | α―2アドレナリン受容体作動薬として有用なグアニジニル複素環式化合物 | |
Chen et al. | Scaffold repurposing of old drugs towards new cancer drug discovery | |
ES2286082T3 (es) | Composiciones terapeuticas que comprenden un exceso de enantiomero de amlodipina. | |
WO2010111951A1 (zh) | 普拉格雷氢溴酸盐的晶体 | |
JPS6015620B2 (ja) | 4―アミノキノリン誘導体 | |
TW200800905A (en) | Substituted 1-amino-4-phenyldihydroisoquinolines, process for their preparation, their use as medicament, and medicament comprising them | |
CA2020171C (en) | Gastroprotective pharmaceutical preparations containing n-benzyl-n-((1s,5s)-6,6-dimethylbicyclo[3,1,1]-hept-2-ylethoxy-ethyl)-morpholinium salts | |
JPH05229943A (ja) | 脳保護剤 | |
WO2003104189A3 (en) | COMPOUNDS | |
RU2574397C1 (ru) | Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в | |
JP3571114B2 (ja) | 麻薬拮抗剤 | |
JPH0769891A (ja) | セロトニン取込み阻害剤 | |
HU211216B (en) | Process for producing novel salts of indometaching and the pharmaceutical compositions comprising them | |
TH70645A (th) | สารประกอบฟิวสด์ เฮเทอโรแอโรแมทิคชนิดใหม่ในฐานะตัวยับยั้งแฟคเตอร์การเจริญเติบโตของการแปลง (tgf) | |
KR20080003601A (ko) | 피롤로피리미디논 유도체의 시트레이트 염 및 이의제조방법 | |
AU2003214439A1 (en) | Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder |